# Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

Study · id `cardio:ct-nct01982292` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01982292](<https://clinicaltrials.gov/study/NCT01982292>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01982292

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.

## Technical summary

Registry record NCT01982292. Randomized; quadruple masking. Start 2014-05 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-11-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking
- Phase: Phase 2
- Enrolled: 321 participants (enrolled count; ClinicalTrials.gov record NCT01982292, source copy `cardio:ctgov-nct01982292-2016-11-09`, retrieved 2026-10-26)
- Start date: 2014-05 (registry gives no type) (ClinicalTrials.gov record NCT01982292, source copy `cardio:ctgov-nct01982292-2016-11-09`, retrieved 2026-10-26)
- Primary completion: 2015-09 (actual) (ClinicalTrials.gov record NCT01982292, source copy `cardio:ctgov-nct01982292-2016-11-09`, retrieved 2026-10-26)
- Completion: 2015-09 (actual) (ClinicalTrials.gov record NCT01982292, source copy `cardio:ctgov-nct01982292-2016-11-09`, retrieved 2026-10-26)
- Results first posted: 2016-11-09 (ClinicalTrials.gov record NCT01982292, source copy `cardio:ctgov-nct01982292-2016-11-09`, retrieved 2026-10-26)
- Countries: United States; Australia; Czechia; Finland; Germany; Italy; Netherlands; Norway; Romania; Russia; Spain; Sweden; Türkiye (ClinicalTrials.gov record NCT01982292, source copy `cardio:ctgov-nct01982292-2016-11-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01982292-2016-11-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
- Acronym: RELAX-REPEAT
- Condition: Chronic Heart Failure
- Intervention (Drug): RLX030 (serelaxin)
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 09d767826c738fe4738d8429e8d1ccc5970c85f7bb87bfd33fa503b3209e58d3
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
